In the context of the tumor environment, several therapies targeting immunosuppressive mediators such as myeloid-derived suppressor cells (MDSCs), regulatory T (Treg) cells, and secreted factors like TGF-β have been used. This evidence concerns the gene TGFB1 and neoplasm.